Colman is a healthcare reimbursement and impact expert with a background working across government, industry and academia. Colman has over a decade of experience in healthcare innovation and holds concurrent academic positions with The George Institute and the University of NSW.
Dr Colman Taylor joined Health Technology Analysts (HTAnalysts, formerly Optum) in May 2014 and was part of a management buy-out in July 2016. During his time with HTAnalysts, Colman has provided strategic oversight for over 500 projects in Australia and the Asia Pacific, working with a diverse variety of companies from local start-ups to international pharmaceutical, digital health and medical device companies. During his career, Colman has contributed to over 100 reimbursement submissions and economic modelling projects, respectively, as well as multiple cost and burden of illness studies, clinical guidelines, market access strategy projects and late phase studies.
As part of HTAnalysts’ role as a member of the Australian Department of Health HTA Panel, Colman has provided guidance and contributed to multiple contracted assessments for Government in diverse areas including genomic screening, investigative technologies such as MRI, and therapeutic technologies such as blue-light cystoscopy. In the area of health policy, Colman has worked with industry and not-for-profit organisations contributing to reports in areas such as funding guidelines for rare disease therapies, biosimilars, and cancer genomics. Colman is currently President-Elect of the Australian ISPOR Committee and regularly contributes to policy workshops focusing on health technology assessment.
Colman has a strong background in academia and currently holds positions with The George Institute for Global Health (Post-Doctoral Research Fellow) and The University of NSW (Conjoint Senior Lecturer). Colman completed his PhD studies at the George Institute – examining the cost and benefit of helicopter emergency medical services. He has been a lead author or co-author on >40 peer-reviewed publications (including The Lancet and NEJM), >45 conference proceedings, and has provided several invited speaker presentations. He is also an active reviewer for several international and local journals and has been granted over $15m in peer-reviewed funding through bodies such as the NHMRC.